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A b s t r A c t
The recently published 2013 ACC/AHA guidelines for the treatment of blood cho-
lesterol to reduce atherosclerotic cardiovascular risk seem to have various imple-
mentation problems and have already initiated an intense debate. These guidelines 
identify 4 high-risk groups who could benefit from statins, patients with pre-existing 
atherosclerotic cardiovascular disease (CVD); people with familial (heterozygous) 
hypercholesterolemia, as evidenced by an LDL-cholesterol (LDL-C) of >190 mg/dl; 
diabetic patients aged 40-75; and people aged 40-75 with at least a 7.5% risk of devel-
oping CVD in the next decade, according to a formula described in the guidelines. In 
contrast to all other guidelines for the management of dyslipidemia, the 2013 ACC/
AHA guidelines do not recommend specific LDL-C targets. Instead, they propose a 
30-50% reduction in LDL-C administering high- or moderate-intensity statin thera-
py depending on the CVD risk. The problems of adopting these new guidelines are 
herein discussed.
L I P I D  G U I D E L I N E s
Elevated serum low-density lipoprotein cholesterol (LDL-C) levels are still a major 
risk factor for cardiovascular disease (CVD) morbidity and mortality; similarly the 
reduced levels of high-density lipoprotein cholesterol (HDL-C) play a role in the patho-
genesis of CVD. The association between elevated triglyceride levels and CVD events 
is more controversial; however, they appear to play even a minor role in atherogenesis. 
Accordingly, the management of dyslipidemias is a major component of primary and 
secondary CVD prevention strategies. In this context, several medical organizations have 
formulated guidelines for the management of dyslipidemias. The first lipid guidelines 
were issued in November of 1985 from the National Cholesterol Education Program 
(NCEP), a branch of the National Heart, Lung, and Blood Institute (NHLBI) of US; 
Europe issued lipid guidelines much later (European Atherosclerosis Society 1989). 
At present time we follow in Greece the first Joint EAS/ESC lipid guidelines issued 
in 2011. These are very simple, because they have one primary target (LDL-C), and 3 
levels of CVD risk with specific LDL-C targets of <115, <100, and <70 mg/dl. EAS/
ESC guidelines have issued coloured charts showing the CVD risk, according to CVD 
risk factors; setting the cut of point (of the SCORE) at 5% risk of fatal CVD during the 
next 10 years (Figure 1). These guidelines encourage the European Countries to issue 
EDItorIAL
2nd Propedeutic Clinic of Internal 
Medicine, Aristotle University of 
Thessaloniki, Thessaloniki, Greece
HOSPITAL CHRONICLES 2014, 9(2): 1–6
Correspondence to:
Prof Vasilios Athyros, 2nd Propedeutic 
Clinic of Internal Medicine, Aristotle 
University, Thessaloniki, Greece; 
E-mail: vathyros@gmail.com
Manuscript received March 4, 2014; 
Revised manuscript accepted March 26, 
2014
KEy WorDs: lipids; atherosclerosis; 
statins; ischemic heart disease; 
guidelines; cardiovascular disease
AbbreviAtions
ACC = American College of Cardiology
AHA = American Heart Association
CHD = coronary heart disease
CVD = cardiovascular disease
EAS = European Atherosclerosis Society
ESC = European Society of Cardiology
LDL = low-density lipoprotein
LDL-C = LDL cholesterol
NCEP = National Cholesterol Education 
Program (NCEP
T2DM = type 2 diabetes mellitus
Conflict of Interest: none declared
2HOSPITAL CHRONICLES 9(2), 2014
their own guidelines according to local data, and Greece was 
the second European Country to do that (HellenicSCORE - a 
Calibration of the ESC SCORE Project, by the group of Profs 
Stefanadis C, Pitsavos C, and Panagiotakos D – Figure 2). All 
the above made the EUROSCORE very easy to implement. Its 
only disadvantage is that it is based on the risk of CVD mortality 
only and does not take into consideration CVD morbidity, as 
it leaves out of the CVD risk calculation non-fatal myocardial 
infarction and non-fatal stroke.
N E W  G U I D E L I N E s
In antithesis, the recently published (12 Nov 2013) ACC/
AHA “Guidelines on the treatment of blood cholesterol to re-
duce atherosclerotic cardiovascular risk in adults” presented at 
the American Heart Association’s Scientific Sessions in Dallas, 
Texas, USA, seem to have various implementation problems 
and have already sparked an intense debate.
The guidelines identify four high-risk groups who could 
benefit from statins:
 - Patients with pre-existing atherosclerotic CVD
 - People with familial (heterozygous) hypercholesterolaemia, 
as evidenced by an LDL-C of 190 mg/dl or higher;
 - Those ages 40 to 75 who have diabetes mellitus;
 - People 40 to 75 with at least a 7.5% risk of developing CVD 
in the next decade, according to a formula described in the 
guidelines (please see below).
In contrast to all other guidelines for the management of 
dyslipidemia, the 2013 Acc/AHA guidelines do not recom-
mend specific LDL-c targets. Instead, they propose a 30-50% 
reduction in LDL-C administering high- or moderate-intensity 
statin therapy depending on the CVD risk (Figures 3 & 4).
 - High-intensity statin therapy includes atorvastatin 40-80 
mg/day and rosuvastatin 20-40 mg/day.
 - Moderate-intensity statin therapy includes atorvastatin 
10-20 mg/day, rosuvastatin 5-10 mg/day, simvastatin 20-40 
mg/day, pravastatin 40-80 mg/day, fluvastatin 40-80 mg/day 
and pitavastatin 2-4 mg/day.
	 •	According	to	the	ACC/AHA	guidelines,	patients	aged	≤75 
years with established atherosclerotic cVD [coronary heart 
disease (CHD), stroke or peripheral arterial disease] and 
subjects with LDL-C levels > 190 mg/dl should be treated 
with high-intensity statin therapy.
	 •	Patients	aged	40-75	years	with type 2 diabetes mellitus 
(t2DM) and LDL-c 70-189 mg/dl but without cVD should 
be treated with high-intensity statin therapy only if their 
estimated 10-year risk for cVD (including cHD death, 
FIGUrE 1. SCORE chart: 10 year risk of fatal cardiovascular 
disease (CVD) in populations at high CVD risk based on the 
following risk factors: age, gender, smoking, systolic blood pres-
sure, and total cholesterol. To convert the risk of fatal CVD 
to risk of total (fatal + non-fatal) hard CVD, multiply by 3 in 
men and 4 in women, and slightly less in old people. Note: the 
SCORE chart is for use in people without overt CVD, diabe-
tes, chronic kidney disease, or very high levels of individual risk 
factors because such people are already at high risk and need 
intensive risk factor advice.
FIGUrE 2
NEw ACC/AHA LIPID GUIDELINES
3
FIGUrE 3. Algorithms for ACC/AHA guidelines.
FIGUrE 4. Algorithms for ACC/AHA guidelines.
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nonfatal myocardial infarction, fatal and nonfatal stroke) 
is ≥7.5% and with moderate-intensity statin therapy if 
their estimated 10-year cVD risk is <7.5%.
	 •	Finally,	patients aged 40-75 years with LDL-c 70-189 
mg/dl but without t2DM or cVD should be treated with 
high- to moderate-intensity statin therapy if their esti-
mated 10-year cVD risk is ≥7.5%, whereas it is reasonable 
to administer moderate-intensity statin therapy if their 
estimated 10-year cVD risk is 5% to <7.5%.
	 •	In other patient groups (i.e. those older than 75 years 
with or without CVD or T2DM and those without CVD 
or T2DM and with 10-year CVD risk < 5%), the use of 
statins should be individualized based on perceived ben-
efits and risks of statin treatment, potential for drug-drug 
interactions, and patient’s preferences.
To estimate 10-year CVD risk, a new equation is proposed, 
the Pooled cohort Equation, derived from data from 5 large 
epidemiological studies (n = 24,626) conducted in US (Athero-
sclerosis Risk in Communities, Cardiovascular Health Study, 
Coronary Artery Risk Development in Young Adults, and 
the Framingham and Framingham Offspring studies). chttp://
my.americanheart.org/professional/statementsGuidelines/
PreventionGuidelines/ Prevention-Guidelines_UcM_457698_
subHomePage.jsp
P r o b L E M s  W I t H  t H E  I M P L E M E N t A t I o N  o F 
2 0 1 3  A c c /A H A  L I P I D  G U I D E L I N E s
1. The guidelines for treatment of dyslipidemia are based solely 
on epidemiological data and not on the results of prospec-
tive, randomized, controlled, interventional, survival trials. 
we are long past from defining CVD (main) risk factors; at 
present we are at difficulty to implement previous simple 
treatment guidelines.
2. The studies used for the equation formula were conducted in 
the US only. Thus, these guidelines might be applicable in 
the US, but they are not probably applicable anywhere else 
in the world (Europe, Asia, Africa, and South America).
3. The guidelines suggest only statin treatment and practically 
ignore all other hypolipidaemic agents; thus, these are 
“statin” and not “lipid” guidelines.
4. The algorithms used to drive the choice of treatment are 
very complex and could not be remembered by all physi-
cians that have to memorize and implement a number of 
algorithms for various other diseases, within their speciality.
5. There is no mention about coronary heart disease (CHD) 
equivalents, such as diabetes mellitus and chronic kidney 
disease (present in the Canadian, the EAS/ESC, and the 
Greek guidelines), as well as their combination (diabetic 
nephropathy has an annual mortality rate of 20%, similar 
to that of cancer). CHD equivalents are ignored at a time 
that other panels and task forces are considering to expand 
the concept of CHD equivalents including rheumatoid 
arthritis, non-alcoholic fatty liver disease or its advanced 
form, non alcoholic steatohepatitis, metabolic syndrome 
with 4-5 components, and others. The ACC/AHA guide-
lines deprive intensive statin treatment from all these high 
CVD patients.
 6. On the other hand, the formula used to calculate risk in 
the ACC/AHA guidelines overestimates CVD risk in those 
without overt CVD of diabetes. There might be an increase 
by up to 150% of the number of primary CVD prevention 
individuals that need statin treatment. Patients on statins 
in US are at present 31.5 million and their number is esti-
mated to rise up to 70 million, if these guidelines are fully 
implemented. It has also been projected that the applica-
tion of the ACC/AHA guidelines worldwide will render 
more than 1 billion subjects eligible for statin treatment. 
The ACC/AHA panel is trying to protect US from the 
upcoming increase of CVD events due to the ever increas-
ing prevalence of obesity, with cheep (generic atorvastatin 
costs less than 5$ a month) statins for everybody. Obesity, 
hypertension, dyslipidemia, type 2 diabetes mellitus, and 
metabolic syndrome are driving the CVD risk in US; CVD 
morbidity and mortality is expected to explode like a bomb 
in the next few years, if drastic measures are not taken. In 
terms of lifestyle changes the situation is disappointing. 
Despite the fact that 70% of US adults are overweight or 
obese, still diet quality continues to deteriorate, leading 
to the fact that at present time the majority of US adults 
display significant lipid abnormalities. However, statin 
for everybody without weighing the risk/benefit ratio is 
dangerous. Statins are known to cause new onset diabetes 
mellitus in up to 24% of people that take them, especially 
in obese people, those with metabolic syndrome, and those 
with prediabetes. Thus, this policy will probably cause a 
boost in the prevalence of diabetes, a major risk factor for 
CVD.
 7. The lack of specific LDL-C targets is a great problem also. 
It is not rare to see in our practice a patient with heterozy-
gous familial hypercholesterolemia and an LDL-C value 
350-400 mg/dl. According to the ACC/AHA guidelines a 
50% reduction is enough. However, is anybody accepting 
the value of 150-200 mg/dl of LDL-C of being at target? 
This suggests that some patients that need intensive hy-
polipidemic (mainly with combinations) drug treatment 
are deprived of it, while others that do not need it are 
considered eligible to receive it.
 8. These guidelines will be an immense barrier that will at least 
delay the use of upcoming in the near future hypolipidemic 
drugs, such as antibodies against PCSK9 (evolocumab and 
alirocumab). These will be commercially available within 
the next two years and are expected to be expensive. These 
have an indication to be used in high CVD risk patients 
that can not reach the <70 mg/dl LDL-C goal with avail-
able treatments. How can one use these drugs if there is no 
specific LDL-C goal over which antibodies against PCSK9 
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should be administered?
 9. Finally, the suggestion of these guidelines is that there is no 
need for follow-up visits and follow-up lab tests in patients 
on statins; the “fire and forget” dogma. This is another way 
to bring down the total cost of statin treatment.
All the above suggest that economic (cost) but not cost/
effectiveness parameters were taken into consideration when 
preparing the ACC/AHA guidelines. This is probably the job of 
a politician rather than the job of a physician. with upcoming 
implementation of the Obamacare both US Administration 
and Legislature are taking into consideration the upcoming 
obesity-related boost in CVD incidence, and put pressure for 
a cheap solution for the treatment of dyslipidaemia, given that 
statins are the best selling drugs ever. However, other countries 
do not have this perspective and they do not need to adopt 
these guidelines. This is the reason that the Task Force of the 
European Atherosclerosis Society/European Society of Cardiol-
ogy, the American Diabetes Association, the American Lipid 
Association, the American Society of Clinical Endocrinolo-
gists, and other smaller Societies from South America or Asia 
declined to endorse these new cholesterol (statin) guidelines 
and suggest to stick with previous guidelines. As a matter of 
fact no other Society adopted these guidelines.
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